Impact of Acyclovir on Genital and Plasma HIV-1 RNA, Genital Herpes Simplex Virus Type 2 DNA, and Ulcer Healing among HIV-1-Infected African Women with Herpes Ulcers: A Randomized Placebo-Controlled Trial
Identifieur interne : 000085 ( PascalFrancis/Curation ); précédent : 000084; suivant : 000086Impact of Acyclovir on Genital and Plasma HIV-1 RNA, Genital Herpes Simplex Virus Type 2 DNA, and Ulcer Healing among HIV-1-Infected African Women with Herpes Ulcers: A Randomized Placebo-Controlled Trial
Auteurs : Philippe Mayaud [Royaume-Uni] ; Jérôme Legoff [France] ; Helen A. Weiss [Royaume-Uni] ; Gérard Gresenguet [France] ; Khonde Nzambi [Ghana] ; Hicham Bouhlal [France] ; Eric Frost [Canada] ; Jacques Pepin [Canada] ; Jean-Elie Malkin [France] ; Richard J. Hayes [Royaume-Uni] ; David C. W. Mabey [Royaume-Uni] ; Laurent Belec [France]Source :
- The Journal of infectious diseases [ 0022-1899 ] ; 2009.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Background. Little is known about the impact of episodic treatment of herpes on human immunodeficiency virus type 1 (HIV-1). Methods. Women from Ghana and the Central African Republic who had genital ulcers were enrolled in a randomized, double-blind, placebo-controlled trial of acyclovir plus antibacterials and were monitored for 28 days. Ulcer etiologies and detection of lesional HIV-1 RNA were determined by polymerase chain reaction (PCR). Cervicovaginal HIV-1 RNA and herpes simplex virus type 2 (HSV-2) DNA and plasma HIV-1 RNA were quantitated by real-time PCR. Primary analyses included 118 HIV-1-infected women with HSV-2 ulcers (54 of whom were given acyclovir and 64 of whom were given placebo). Results. Acyclovir had little impact on (1) detection of cervicovaginal HIV-1 RNA (risk ratio [RR], 0.96; 95% confidence interval [CI], 0.8-1.2) at day 7 of treatment, (2) the mean cervicovaginal HIV-1 RNA load (-0.06 log10 copies/mL; 95% CI, -0.4 to 0.3 log10 copies/mL) at day 7 of treatment, or (3) the plasma HIV-1 RNA load (+0.09 log10 copies/mL; 95% CI, -0.1 to 0.3 log10 copies/mL) at day 14 of treatment. At day 7, women receiving acyclovir were less likely to have detectable lesional HIV-1 RNA (RR, 0.70; 95% CI, 0.4-1.2) or cervicovaginal HSV-2 DNA (RR, 0.69; 95% CI, 0.4-1.3), had a lower quantity of HSV-2 DNA (-0.99 log10 copies/mL; 95% CI, - 1.8 to -0.2 log10 copies/mL), and were more likely to have a healed ulcer (RR, 1.26; 95% CI, 0.9-1.9). Conclusion. Episodic therapy for herpes reduced the quantity of cervicovaginal HSV-2 DNA and slightly improved ulcer healing, but it did not decrease genital and plasma HIV-1 RNA loads.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000052
Links to Exploration step
Pascal:09-0339639Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Impact of Acyclovir on Genital and Plasma HIV-1 RNA, Genital Herpes Simplex Virus Type 2 DNA, and Ulcer Healing among HIV-1-Infected African Women with Herpes Ulcers: A Randomized Placebo-Controlled Trial</title><author><name sortKey="Mayaud, Philippe" sort="Mayaud, Philippe" uniqKey="Mayaud P" first="Philippe" last="Mayaud">Philippe Mayaud</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Legoff, Jerome" sort="Legoff, Jerome" uniqKey="Legoff J" first="Jérôme" last="Legoff">Jérôme Legoff</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centre de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1><s3>FRA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Université Paris Diderot, Laboratoire de Microbiologie, Hôpital Saint-Louis</s1><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Weiss, Helen A" sort="Weiss, Helen A" uniqKey="Weiss H" first="Helen A." last="Weiss">Helen A. Weiss</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Infectious Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>3 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Gresenguet, Gerard" sort="Gresenguet, Gerard" uniqKey="Gresenguet G" first="Gérard" last="Gresenguet">Gérard Gresenguet</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Centre National de Référence des Maladies Sexuellement Transmissibles et du SIDA de Bangui and Unité de Recherches et d'Intervention sur les Maladies Sexuellement Transmissibles et du SIDA, Faculté des Sciences de la Santé</s1><s2>Bangui</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Nzambi, Khonde" sort="Nzambi, Khonde" uniqKey="Nzambi K" first="Khonde" last="Nzambi">Khonde Nzambi</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Central African Republic; 'West African Project To Combat AIDS and STIs</s1><s2>Accra</s2><s3>GHA</s3><sZ>5 aut.</sZ></inist:fA14><country>Ghana</country></affiliation></author><author><name sortKey="Bouhlal, Hicham" sort="Bouhlal, Hicham" uniqKey="Bouhlal H" first="Hicham" last="Bouhlal">Hicham Bouhlal</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centre de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1><s3>FRA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Frost, Eric" sort="Frost, Eric" uniqKey="Frost E" first="Eric" last="Frost">Eric Frost</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Centre for International Health, University of Sherbrooke</s1><s2>Sherbrooke</s2><s3>CAN</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Pepin, Jacques" sort="Pepin, Jacques" uniqKey="Pepin J" first="Jacques" last="Pepin">Jacques Pepin</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Centre for International Health, University of Sherbrooke</s1><s2>Sherbrooke</s2><s3>CAN</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Malkin, Jean Elie" sort="Malkin, Jean Elie" uniqKey="Malkin J" first="Jean-Elie" last="Malkin">Jean-Elie Malkin</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Centre Médical, Institut Pasteur</s1><s2>Paris</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Hayes, Richard J" sort="Hayes, Richard J" uniqKey="Hayes R" first="Richard J." last="Hayes">Richard J. Hayes</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Infectious Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>3 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Mabey, David C W" sort="Mabey, David C W" uniqKey="Mabey D" first="David C. W." last="Mabey">David C. W. Mabey</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Belec, Laurent" sort="Belec, Laurent" uniqKey="Belec L" first="Laurent" last="Belec">Laurent Belec</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centre de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1><s3>FRA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>France</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0339639</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 09-0339639 INIST</idno><idno type="RBID">Pascal:09-0339639</idno><idno type="wicri:Area/PascalFrancis/Corpus">000052</idno><idno type="wicri:Area/PascalFrancis/Curation">000085</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Impact of Acyclovir on Genital and Plasma HIV-1 RNA, Genital Herpes Simplex Virus Type 2 DNA, and Ulcer Healing among HIV-1-Infected African Women with Herpes Ulcers: A Randomized Placebo-Controlled Trial</title><author><name sortKey="Mayaud, Philippe" sort="Mayaud, Philippe" uniqKey="Mayaud P" first="Philippe" last="Mayaud">Philippe Mayaud</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Legoff, Jerome" sort="Legoff, Jerome" uniqKey="Legoff J" first="Jérôme" last="Legoff">Jérôme Legoff</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centre de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1><s3>FRA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Université Paris Diderot, Laboratoire de Microbiologie, Hôpital Saint-Louis</s1><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Weiss, Helen A" sort="Weiss, Helen A" uniqKey="Weiss H" first="Helen A." last="Weiss">Helen A. Weiss</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Infectious Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>3 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Gresenguet, Gerard" sort="Gresenguet, Gerard" uniqKey="Gresenguet G" first="Gérard" last="Gresenguet">Gérard Gresenguet</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Centre National de Référence des Maladies Sexuellement Transmissibles et du SIDA de Bangui and Unité de Recherches et d'Intervention sur les Maladies Sexuellement Transmissibles et du SIDA, Faculté des Sciences de la Santé</s1><s2>Bangui</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Nzambi, Khonde" sort="Nzambi, Khonde" uniqKey="Nzambi K" first="Khonde" last="Nzambi">Khonde Nzambi</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Central African Republic; 'West African Project To Combat AIDS and STIs</s1><s2>Accra</s2><s3>GHA</s3><sZ>5 aut.</sZ></inist:fA14><country>Ghana</country></affiliation></author><author><name sortKey="Bouhlal, Hicham" sort="Bouhlal, Hicham" uniqKey="Bouhlal H" first="Hicham" last="Bouhlal">Hicham Bouhlal</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centre de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1><s3>FRA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Frost, Eric" sort="Frost, Eric" uniqKey="Frost E" first="Eric" last="Frost">Eric Frost</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Centre for International Health, University of Sherbrooke</s1><s2>Sherbrooke</s2><s3>CAN</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Pepin, Jacques" sort="Pepin, Jacques" uniqKey="Pepin J" first="Jacques" last="Pepin">Jacques Pepin</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Centre for International Health, University of Sherbrooke</s1><s2>Sherbrooke</s2><s3>CAN</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Malkin, Jean Elie" sort="Malkin, Jean Elie" uniqKey="Malkin J" first="Jean-Elie" last="Malkin">Jean-Elie Malkin</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Centre Médical, Institut Pasteur</s1><s2>Paris</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Hayes, Richard J" sort="Hayes, Richard J" uniqKey="Hayes R" first="Richard J." last="Hayes">Richard J. Hayes</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Infectious Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>3 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Mabey, David C W" sort="Mabey, David C W" uniqKey="Mabey D" first="David C. W." last="Mabey">David C. W. Mabey</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Clinical Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Belec, Laurent" sort="Belec, Laurent" uniqKey="Belec L" first="Laurent" last="Belec">Laurent Belec</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centre de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1><s3>FRA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>France</country></affiliation></author></analytic><series><title level="j" type="main">The Journal of infectious diseases</title><title level="j" type="abbreviated">J. infect. dis.</title><idno type="ISSN">0022-1899</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">The Journal of infectious diseases</title><title level="j" type="abbreviated">J. infect. dis.</title><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term><term>Aciclovir</term><term>Antiviral</term><term>Female</term><term>Genital herpes</term><term>HIV-1 virus</term><term>Human</term><term>Human herpesvirus 2</term><term>Microbiology</term><term>Ulcer</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Virus HIV1</term><term>Herpesvirus hominis 2</term><term>Homme</term><term>Herpès génital</term><term>Ulcère</term><term>SIDA</term><term>Femelle</term><term>Microbiologie</term><term>Aciclovir</term><term>Antiviral</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background. Little is known about the impact of episodic treatment of herpes on human immunodeficiency virus type 1 (HIV-1). Methods. Women from Ghana and the Central African Republic who had genital ulcers were enrolled in a randomized, double-blind, placebo-controlled trial of acyclovir plus antibacterials and were monitored for 28 days. Ulcer etiologies and detection of lesional HIV-1 RNA were determined by polymerase chain reaction (PCR). Cervicovaginal HIV-1 RNA and herpes simplex virus type 2 (HSV-2) DNA and plasma HIV-1 RNA were quantitated by real-time PCR. Primary analyses included 118 HIV-1-infected women with HSV-2 ulcers (54 of whom were given acyclovir and 64 of whom were given placebo). Results. Acyclovir had little impact on (1) detection of cervicovaginal HIV-1 RNA (risk ratio [RR], 0.96; 95% confidence interval [CI], 0.8-1.2) at day 7 of treatment, (2) the mean cervicovaginal HIV-1 RNA load (-0.06 log<sub>10</sub> copies/mL; 95% CI, -0.4 to 0.3 log<sub>10</sub> copies/mL) at day 7 of treatment, or (3) the plasma HIV-1 RNA load (+0.09 log<sub>10</sub> copies/mL; 95% CI, -0.1 to 0.3 log<sub>10</sub> copies/mL) at day 14 of treatment. At day 7, women receiving acyclovir were less likely to have detectable lesional HIV-1 RNA (RR, 0.70; 95% CI, 0.4-1.2) or cervicovaginal HSV-2 DNA (RR, 0.69; 95% CI, 0.4-1.3), had a lower quantity of HSV-2 DNA (-0.99 log<sub>10</sub> copies/mL; 95% CI, - 1.8 to -0.2 log<sub>10</sub> copies/mL), and were more likely to have a healed ulcer (RR, 1.26; 95% CI, 0.9-1.9). Conclusion. Episodic therapy for herpes reduced the quantity of cervicovaginal HSV-2 DNA and slightly improved ulcer healing, but it did not decrease genital and plasma HIV-1 RNA loads.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-1899</s0></fA01><fA02 i1="01"><s0>JIDIAQ</s0></fA02><fA03 i2="1"><s0>J. infect. dis.</s0></fA03><fA05><s2>200</s2></fA05><fA06><s2>2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Impact of Acyclovir on Genital and Plasma HIV-1 RNA, Genital Herpes Simplex Virus Type 2 DNA, and Ulcer Healing among HIV-1-Infected African Women with Herpes Ulcers: A Randomized Placebo-Controlled Trial</s1></fA08><fA11 i1="01" i2="1"><s1>MAYAUD (Philippe)</s1></fA11><fA11 i1="02" i2="1"><s1>LEGOFF (Jérôme)</s1></fA11><fA11 i1="03" i2="1"><s1>WEISS (Helen A.)</s1></fA11><fA11 i1="04" i2="1"><s1>GRESENGUET (Gérard)</s1></fA11><fA11 i1="05" i2="1"><s1>NZAMBI (Khonde)</s1></fA11><fA11 i1="06" i2="1"><s1>BOUHLAL (Hicham)</s1></fA11><fA11 i1="07" i2="1"><s1>FROST (Eric)</s1></fA11><fA11 i1="08" i2="1"><s1>PEPIN (Jacques)</s1></fA11><fA11 i1="09" i2="1"><s1>MALKIN (Jean-Elie)</s1></fA11><fA11 i1="10" i2="1"><s1>HAYES (Richard J.)</s1></fA11><fA11 i1="11" i2="1"><s1>MABEY (David C. W.)</s1></fA11><fA11 i1="12" i2="1"><s1>BELEC (Laurent)</s1></fA11><fA14 i1="01"><s1>Clinical Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ></fA14><fA14 i1="02"><s1>Infectious Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</s1><s2>London</s2><s3>GBR</s3><sZ>3 aut.</sZ><sZ>10 aut.</sZ></fA14><fA14 i1="03"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centre de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1><s3>FRA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>12 aut.</sZ></fA14><fA14 i1="04"><s1>Université Paris Diderot, Laboratoire de Microbiologie, Hôpital Saint-Louis</s1><s3>FRA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="05"><s1>Centre Médical, Institut Pasteur</s1><s2>Paris</s2><s3>FRA</s3><sZ>9 aut.</sZ></fA14><fA14 i1="06"><s1>Centre National de Référence des Maladies Sexuellement Transmissibles et du SIDA de Bangui and Unité de Recherches et d'Intervention sur les Maladies Sexuellement Transmissibles et du SIDA, Faculté des Sciences de la Santé</s1><s2>Bangui</s2><s3>FRA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="07"><s1>Central African Republic; 'West African Project To Combat AIDS and STIs</s1><s2>Accra</s2><s3>GHA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="08"><s1>Centre for International Health, University of Sherbrooke</s1><s2>Sherbrooke</s2><s3>CAN</s3><sZ>7 aut.</sZ><sZ>8 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>ANRS 1212 Study Group</s1><s3>INC</s3></fA17><fA20><s1>216-226</s1></fA20><fA21><s1>2009</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>2052</s2><s5>354000187517850090</s5></fA43><fA44><s0>0000</s0><s1>© 2009 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>47 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>09-0339639</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>The Journal of infectious diseases</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Background. Little is known about the impact of episodic treatment of herpes on human immunodeficiency virus type 1 (HIV-1). Methods. Women from Ghana and the Central African Republic who had genital ulcers were enrolled in a randomized, double-blind, placebo-controlled trial of acyclovir plus antibacterials and were monitored for 28 days. Ulcer etiologies and detection of lesional HIV-1 RNA were determined by polymerase chain reaction (PCR). Cervicovaginal HIV-1 RNA and herpes simplex virus type 2 (HSV-2) DNA and plasma HIV-1 RNA were quantitated by real-time PCR. Primary analyses included 118 HIV-1-infected women with HSV-2 ulcers (54 of whom were given acyclovir and 64 of whom were given placebo). Results. Acyclovir had little impact on (1) detection of cervicovaginal HIV-1 RNA (risk ratio [RR], 0.96; 95% confidence interval [CI], 0.8-1.2) at day 7 of treatment, (2) the mean cervicovaginal HIV-1 RNA load (-0.06 log<sub>10</sub> copies/mL; 95% CI, -0.4 to 0.3 log<sub>10</sub> copies/mL) at day 7 of treatment, or (3) the plasma HIV-1 RNA load (+0.09 log<sub>10</sub> copies/mL; 95% CI, -0.1 to 0.3 log<sub>10</sub> copies/mL) at day 14 of treatment. At day 7, women receiving acyclovir were less likely to have detectable lesional HIV-1 RNA (RR, 0.70; 95% CI, 0.4-1.2) or cervicovaginal HSV-2 DNA (RR, 0.69; 95% CI, 0.4-1.3), had a lower quantity of HSV-2 DNA (-0.99 log<sub>10</sub> copies/mL; 95% CI, - 1.8 to -0.2 log<sub>10</sub> copies/mL), and were more likely to have a healed ulcer (RR, 1.26; 95% CI, 0.9-1.9). Conclusion. Episodic therapy for herpes reduced the quantity of cervicovaginal HSV-2 DNA and slightly improved ulcer healing, but it did not decrease genital and plasma HIV-1 RNA loads.</s0></fC01><fC02 i1="01" i2="X"><s0>002A05C10</s0></fC02><fC02 i1="02" i2="X"><s0>002B05C02D</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Virus HIV1</s0><s2>NW</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>HIV-1 virus</s0><s2>NW</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>HIV-1 virus</s0><s2>NW</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Herpesvirus hominis 2</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Human herpesvirus 2</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Herpesvirus hominis 2</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Human</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Herpès génital</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Genital herpes</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Herpes genital</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Ulcère</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Ulcer</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Ulcera</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>SIDA</s0><s5>07</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>AIDS</s0><s5>07</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>SIDA</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Femelle</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Female</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Hembra</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Microbiologie</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Microbiology</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Microbiología</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Aciclovir</s0><s2>NK</s2><s2>FR</s2><s5>14</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Aciclovir</s0><s2>NK</s2><s2>FR</s2><s5>14</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Aciclovir</s0><s2>NK</s2><s2>FR</s2><s5>14</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Antiviral</s0><s5>15</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Antiviral</s0><s5>15</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Antiviral</s0><s5>15</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Virus immunodéficience humaine</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Human immunodeficiency virus</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Human immunodeficiency virus</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Lentivirus</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Lentivirus</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Lentivirus</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Retroviridae</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Alphaherpesvirinae</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Alphaherpesvirinae</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Alphaherpesvirinae</s0><s2>NW</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Herpesviridae</s0><s2>NW</s2></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Herpesviridae</s0><s2>NW</s2></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Herpesviridae</s0><s2>NW</s2></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Infección</s0></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Nucléoside acyclique</s0><s5>13</s5></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Acyclic nucleoside</s0><s5>13</s5></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Nucleósido acíclico</s0><s5>13</s5></fC07><fC07 i1="10" i2="X" l="FRE"><s0>Purine nucléoside</s0><s5>16</s5></fC07><fC07 i1="10" i2="X" l="ENG"><s0>Purine nucleoside</s0><s5>16</s5></fC07><fC07 i1="10" i2="X" l="SPA"><s0>Purina nucleósido</s0><s5>16</s5></fC07><fC07 i1="11" i2="X" l="FRE"><s0>Analogue de nucléoside</s0><s5>17</s5></fC07><fC07 i1="11" i2="X" l="ENG"><s0>Nucleoside analog</s0><s5>17</s5></fC07><fC07 i1="11" i2="X" l="SPA"><s0>Análogo nucleósido</s0><s5>17</s5></fC07><fC07 i1="12" i2="X" l="FRE"><s0>Inhibiteur de l'ADN polymérase</s0><s5>18</s5></fC07><fC07 i1="12" i2="X" l="ENG"><s0>DNA polymerase inhibitor</s0><s5>18</s5></fC07><fC07 i1="12" i2="X" l="SPA"><s0>Inhibidor DNA polymerase</s0><s5>18</s5></fC07><fC07 i1="13" i2="X" l="FRE"><s0>Pathologie de l'appareil génital</s0><s5>19</s5></fC07><fC07 i1="13" i2="X" l="ENG"><s0>Genital diseases</s0><s5>19</s5></fC07><fC07 i1="13" i2="X" l="SPA"><s0>Aparato genital patología</s0><s5>19</s5></fC07><fC07 i1="14" i2="X" l="FRE"><s0>Maladie sexuellement transmissible</s0><s5>20</s5></fC07><fC07 i1="14" i2="X" l="ENG"><s0>Sexually transmitted disease</s0><s5>20</s5></fC07><fC07 i1="14" i2="X" l="SPA"><s0>Enfermedad de transmisión sexual</s0><s5>20</s5></fC07><fC07 i1="15" i2="X" l="FRE"><s0>Immunodéficit</s0><s5>21</s5></fC07><fC07 i1="15" i2="X" l="ENG"><s0>Immune deficiency</s0><s5>21</s5></fC07><fC07 i1="15" i2="X" l="SPA"><s0>Inmunodeficiencia</s0><s5>21</s5></fC07><fC07 i1="16" i2="X" l="FRE"><s0>Immunopathologie</s0><s5>23</s5></fC07><fC07 i1="16" i2="X" l="ENG"><s0>Immunopathology</s0><s5>23</s5></fC07><fC07 i1="16" i2="X" l="SPA"><s0>Inmunopatología</s0><s5>23</s5></fC07><fN21><s1>243</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000085 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000085 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:09-0339639
|texte= Impact of Acyclovir on Genital and Plasma HIV-1 RNA, Genital Herpes Simplex Virus Type 2 DNA, and Ulcer Healing among HIV-1-Infected African Women with Herpes Ulcers: A Randomized Placebo-Controlled Trial
}}
| This area was generated with Dilib version V0.6.31. |  |